The Administrative Core will provide several essential functions to this program project. (1) The Core will supply grant management services to the five Projects and the Biostatistics Core (Core B) in this program. This Core will provide financial, administrative, clerical, and secretarial services for the Principal Investigator (Tom Look), co-Principal Investigator (Harald von Boehmer), Project Leaders (Peter Sicinski, Fred Alt, Rick Young, Harald von Boehmer and Tom Look), and Core Directors (Donna Neuberg and Tom Look) for Program-related grant activities. These activities include preparation of progress reports, preparation of budgets, communication with the NIH regarding renewals and all financial interactions, assurance that the labs supported by this Program are in compliance with all institutional, state, and federal regulations. This will include working with the investigators at the Immune Diseases Institute and Whitehead Institute, Massachusetts Institute of Technology. (2) The core will be responsible for organizing and coordinating the numerous meetings that will serve as the foundation for scientific interaction and review of the program. These include meetings of the scientific team, of the project leaders and Core Directors, and with members of the External and Internal Advisory boards. Tom Look, the PI of the program project will serve as Director of this Core and scientific director and chief administrator of the Program Project. Harald von Boehmer will serve as Co-Director for the administrative core and as such will act as Co-Investigator for the program project, assisting in administrative aspects of the core and acting as Principal Investigator in Dr. Look's absence. Doris Dodson will be responsible for preparing communications and reports to the NIH, for preparing the grant applications, for setting up the numerous meetings that are part of this Program, and assisting with the travel and agendas of the external reviewers and she will assist Dr. Look with record keeping and she will monitor animal and biosafety protocols involved in the Program and help prepare annual noncompeting progress reports for the NCI.
Successful completion of this 5-year renewal of our program will improve understanding of how T-cell regulatory pathways are disrupted to initiate and maintain the transformed phenotype in T-ALL and T-LBL, with the long-term goal to pinpoint genes whose inhibition could lead to the development of new and highly specific treatment strategies for these malignant diseases.
|Mansour, Marc R; He, Shuning; Li, Zhaodong et al. (2018) JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. J Exp Med 215:1929-1945|
|Lobbardi, Riadh; Pinder, Jordan; Martinez-Pastor, Barbara et al. (2017) TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discov 7:1336-1353|
|Rahman, Sunniyat; Magnussen, Michael; León, Theresa E et al. (2017) Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood 129:3221-3226|
|Abraham, Brian J; Hnisz, Denes; Weintraub, Abraham S et al. (2017) Small genomic insertions form enhancers that misregulate oncogenes. Nat Commun 8:14385|
|Li, Z; Abraham, B J; Berezovskaya, A et al. (2017) APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL. Leukemia 31:2057-2064|
|Winter, Georg E; Mayer, Andreas; Buckley, Dennis L et al. (2017) BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Mol Cell 67:5-18.e19|
|Erb, Michael A; Scott, Thomas G; Li, Bin E et al. (2017) Transcription control by the ENL YEATS domain in acute leukaemia. Nature 543:270-274|
|Akahane, K; Sanda, T; Mansour, M R et al. (2016) HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia 30:219-28|
|Zhang, Tinghu; Kwiatkowski, Nicholas; Olson, Calla M et al. (2016) Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol 12:876-84|
|Hnisz, Denes; Weintraub, Abraham S; Day, Daniel S et al. (2016) Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science 351:1454-1458|
Showing the most recent 10 out of 63 publications